Alpine Immune Sciences Inc buy marge
Summary
This prediction ended on 20.12.18 with a price of €4.18. Massive losses of -56.81% were the result for the BUY prediction by marge. marge has 50% into this predictionAlpine Immune Sciences is a clinical-stage biotechnology company focused on developing novel therapies that modulate the immune system to treat cancer, autoimmune, and inflammatory diseases. The company's proprietary platform technology, called "Variant Ig Domain" (vIgD), enables the design and development of unique protein therapeutics that can target specific immune cells and pathways. Alpine's lead product candidate, ALPN-202, is a dual ICOS/CD28 antagonist for the treatment of autoimmune and inflammatory diseases, and the company has several other product candidates in preclinical development. Alpine Immune Sciences is listed on the NASDAQ stock exchange under the ticker symbol "ALPN".
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alpine Immune Sciences Inc | - | - | - | - |
iShares Core DAX® | 1.280% | 1.027% | 11.234% | 16.273% |
iShares Nasdaq 100 | -2.457% | -4.650% | 23.181% | 39.418% |
iShares Nikkei 225® | -2.006% | -2.091% | 6.745% | 6.545% |
iShares S&P 500 | -0.662% | -1.246% | 22.521% | 40.218% |
Comments by marge for this prediction
In the thread Alpine Immune Sciences Inc diskutieren
marge stimmt der Buy-Einschätzung von klostergang zu
marge stimmt am 19.04.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 6$ zu.
Überschrift: Nivalis massiv unter Cash gehandelt
- Nivalis Therapeutics (NASDAQ:NVLS) +26.9% AH after disclosing it will merge with Alpine Immune Sciences in an all-stock deal.
-
Alpine will take over
what is essentially a non-operating NVLS shell company following the
January failure of a cystic fibrosis drug clinical trial; once the
merger is complete in Q3, the combined companies will take the Alpine
Immune Sciences name and focus on its pipeline of protein-based
immunotherapy drugs.